Blood-Guided chemo dosing study for colon cancer withdrawn
NCT ID NCT06501989
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study aimed to see if adjusting the dose of the chemotherapy drug 5-FU based on its concentration in the blood could improve treatment for metastatic colorectal cancer. The study was withdrawn before enrolling any participants. It was designed for adults with metastatic colorectal cancer who had not received prior treatment for their metastatic disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Started
-
Sep 2025
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Males or females at least 18 years of age. * Histologically confirmed metastatic colorectal cancer eligible for treatment with 5-FU. * No prior therapy for metastatic disease. If adjuvant 5-FU or FOLFOX was administered, the last dose must have been at least 6 months prior to the diagnosis of metastatic disease. * Adequate organ function. * Eastern Cooperative Oncology Group (ECOG) status less than or equal to 2. * Life expectancy \> 3 months. Exclusion Criteria: * Untreated brain metastasis. Treated brain metastases are allowed as long as symptoms have resolved off of steroids. * At least 4 weeks from any prior surgery or 2 weeks from radiation treatments. * Known dihydropyrimidine dehydrogenase (DPD) deficiency.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic colorectal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Inova Health Care Service
Falls Church, Virginia, 22042, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a hyaluronic acid drug combo outperform bevacizumab in Hard-to-Treat colon cancer?
- Can a targeted drug boost chemotherapy in advanced colorectal cancer?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Two-Step PET scan aims to spot hidden colorectal cancer spread
- Can a targeted drug conjugate outsmart advanced colorectal cancer?
- Can an antimalarial drug boost immunotherapy against colorectal cancer?